Mar 22, 2023
|
-- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- BOSTON --(BUSINESS WIRE)--Mar. 22, 2023-- Spectrum Pharmaceuticals, Inc.
|
|
Mar 17, 2023
|
BOSTON --(BUSINESS WIRE)--Mar. 17, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a
|
|
Feb 08, 2023
|
BOSTON --(BUSINESS WIRE)--Feb. 8, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S.
|
|
Jan 31, 2023
|
-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million -- -- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024 -- BOSTON --(BUSINESS WIRE)--Jan. 31, 2023-- Spectrum Pharmaceuticals, Inc.
|
|
Jan 26, 2023
|
-- Commercial employee (non-executive) who was hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection is the recipient of this grant -- BOSTON --(BUSINESS WIRE)--Jan. 26, 2023-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
|
|
Jan 04, 2023
|
BOSTON --(BUSINESS WIRE)--Jan. 4, 2023-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel , M.D., Executive Vice President and Chief Medical Officer, will step down from his role to
|
|
Dec 27, 2022
|
-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- BOSTON --(BUSINESS WIRE)--Dec. 27, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
|
|
Dec 06, 2022
|
BOSTON --(BUSINESS WIRE)--Dec. 6, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network® Supportive Care
|
|
Dec 05, 2022
|
-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- BOSTON --(BUSINESS WIRE)--Dec. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
|
|
Nov 25, 2022
|
— Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce — — Spectrum to explore strategic alternatives for the poziotinib program, including partnerships and business development opportunities — BOSTON --(BUSINESS WIRE)--Nov.
|
|
Nov 10, 2022
|
-- ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available -- -- Cash runway expected to extend through 2024 -- -- Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT -- BOSTON --(BUSINESS WIRE)--Nov. 10, 2022-- Spectrum Pharmaceuticals, Inc.
|
|
Nov 03, 2022
|
BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update
|
|
Oct 21, 2022
|
-- Distribution partners stocked with product and ready to sell into estimated $2 billion market -- BOSTON --(BUSINESS WIRE)--Oct. 21, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies,
|
|
Sep 23, 2022
|
-- Multiple tranche debt financing provides Spectrum with up to $65 million -- -- Funding provides additional capital to optimize commercial launch of ROLVEDON™ -- -- Cash runway extended through 2024 -- BOSTON --(BUSINESS WIRE)--Sep. 23, 2022-- Spectrum Pharmaceuticals, Inc.
|
|
Sep 22, 2022
|
BOSTON --(BUSINESS WIRE)--Sep. 22, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee
|
|
Sep 10, 2022
|
BOSTON --(BUSINESS WIRE)--Sep. 10, 2022-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion
|
|
Sep 09, 2022
|
First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON ™ developed using proprietary LAPSCOVERY ™ technology with a differentiated molecular structure and proven safety and efficacy profile Commercial team ready to launch with product available in the fourth quarter
|
|
Sep 05, 2022
|
BOSTON --(BUSINESS WIRE)--Sep. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small
|
|
Aug 11, 2022
|
Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022 Management to host webcast and conference call today at 8:30 a.m.
|
|
Jul 29, 2022
|
HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 29, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate
|
|